25 XP   0   0   10

NeoGenomics Inc
Buy, Hold or Sell?

Let's analyse Neogenomics together

PenkeI guess you are interested in NeoGenomics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NeoGenomics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about NeoGenomics Inc

I send you an email if I find something interesting about NeoGenomics Inc.

Quick analysis of Neogenomics (30 sec.)










What can you expect buying and holding a share of Neogenomics? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$7.38
Expected worth in 1 year
$6.94
How sure are you?
67.5%

+ What do you gain per year?

Total Gains per Share
$-0.44
Return On Investment
-2.9%

For what price can you sell your share?

Current Price per Share
$15.22
Expected price per share
$11.03 - $15.86
How sure are you?
50%

1. Valuation of Neogenomics (5 min.)




Live pricePrice per Share (EOD)

$15.22

Intrinsic Value Per Share

$-2.99 - $5.90

Total Value Per Share

$4.38 - $13.28

2. Growth of Neogenomics (5 min.)




Is Neogenomics growing?

Current yearPrevious yearGrowGrow %
How rich?$941.5m$1b-$77.4m-8.1%

How much money is Neogenomics making?

Current yearPrevious yearGrowGrow %
Making money-$21.9m-$36m$14m64.0%
Net Profit Margin-15.1%-28.8%--

How much money comes from the company's main activities?

3. Financial Health of Neogenomics (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#34 / 145

Most Revenue
#51 / 145

Most Profit
#123 / 145

What can you expect buying and holding a share of Neogenomics? (5 min.)

Welcome investor! Neogenomics's management wants to use your money to grow the business. In return you get a share of Neogenomics.

What can you expect buying and holding a share of Neogenomics?

First you should know what it really means to hold a share of Neogenomics. And how you can make/lose money.

Speculation

The Price per Share of Neogenomics is $15.22. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neogenomics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neogenomics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.38. Based on the TTM, the Book Value Change Per Share is $-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neogenomics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.11-0.7%-0.17-1.1%-0.28-1.9%-0.09-0.6%-0.05-0.3%
Usd Book Value Change Per Share-0.05-0.3%-0.11-0.7%-0.22-1.4%0.241.6%0.181.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.05-0.3%-0.11-0.7%-0.22-1.4%0.241.6%0.181.2%
Usd Price Per Share16.18-15.49-9.54-25.80-16.84-
Price to Earnings Ratio-36.03--24.08--8.91-26.60--4.07-
Price-to-Total Gains Ratio-350.49--184.03--48.60--3.57-96.37-
Price to Book Ratio2.19-2.07-1.18-4.54-6.36-
Price-to-Total Gains Ratio-350.49--184.03--48.60--3.57-96.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share15.22
Number of shares65
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.110.24
Usd Total Gains Per Share-0.110.24
Gains per Quarter (65 shares)-7.1915.82
Gains per Year (65 shares)-28.7763.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-29-3906353
20-58-680127116
30-86-970190179
40-115-1260253242
50-144-1550316305
60-173-1840380368
70-201-2130443431
80-230-2420506494
90-259-2710569557
100-288-3000633620

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%6.014.00.030.0%13.027.00.032.5%28.068.00.029.2%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%10.010.00.050.0%27.013.00.067.5%49.039.08.051.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%2.00.094.02.1%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%10.010.00.050.0%27.013.00.067.5%50.039.07.052.1%

Fundamentals of Neogenomics

About NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Fundamental data was last updated by Penke on 2024-04-11 15:43:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of NeoGenomics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Neogenomics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -9.2% means that $-0.09 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NeoGenomics Inc:

  • The MRQ is -9.2%. The company is making a loss. -1
  • The TTM is -15.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-9.2%TTM-15.1%+5.9%
TTM-15.1%YOY-28.8%+13.7%
TTM-15.1%5Y-8.8%-6.3%
5Y-8.8%10Y-4.7%-4.1%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.2%-7.3%-1.9%
TTM-15.1%-6.7%-8.4%
YOY-28.8%-1.9%-26.9%
5Y-8.8%-1.5%-7.3%
10Y-4.7%-3.4%-1.3%
1.1.2. Return on Assets

Shows how efficient Neogenomics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • -0.9% Return on Assets means that Neogenomics generated $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NeoGenomics Inc:

  • The MRQ is -0.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.9%TTM-1.3%+0.4%
TTM-1.3%YOY-2.0%+0.7%
TTM-1.3%5Y-0.6%-0.7%
5Y-0.6%10Y-0.4%-0.3%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.9%-1.3%+0.4%
TTM-1.3%-1.3%+0.0%
YOY-2.0%-0.9%-1.1%
5Y-0.6%-0.5%-0.1%
10Y-0.4%-0.9%+0.5%
1.1.3. Return on Equity

Shows how efficient Neogenomics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • -1.5% Return on Equity means Neogenomics generated $-0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NeoGenomics Inc:

  • The MRQ is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM-2.3%+0.8%
TTM-2.3%YOY-3.5%+1.2%
TTM-2.3%5Y-1.2%-1.1%
5Y-1.2%10Y-0.6%-0.5%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.5%-0.5%-1.0%
TTM-2.3%0.2%-2.5%
YOY-3.5%-0.1%-3.4%
5Y-1.2%-1.4%+0.2%
10Y-0.6%-2.3%+1.7%

1.2. Operating Efficiency of NeoGenomics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Neogenomics is operating .

  • Measures how much profit Neogenomics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • An Operating Margin of -6.2% means the company generated $-0.06  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NeoGenomics Inc:

  • The MRQ is -6.2%. The company is operating very inefficient. -2
  • The TTM is -14.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6.2%TTM-14.4%+8.2%
TTM-14.4%YOY-31.2%+16.8%
TTM-14.4%5Y-10.1%-4.3%
5Y-10.1%10Y-5.8%-4.3%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.2%-7.4%+1.2%
TTM-14.4%0.5%-14.9%
YOY-31.2%4.0%-35.2%
5Y-10.1%3.7%-13.8%
10Y-5.8%-1.3%-4.5%
1.2.2. Operating Ratio

Measures how efficient Neogenomics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 1.11 means that the operating costs are $1.11 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NeoGenomics Inc:

  • The MRQ is 1.112. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.165. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.112TTM1.165-0.054
TTM1.165YOY1.312-0.147
TTM1.1655Y1.147+0.018
5Y1.14710Y1.069+0.078
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1121.280-0.168
TTM1.1651.304-0.139
YOY1.3121.236+0.076
5Y1.1471.242-0.095
10Y1.0691.205-0.136

1.3. Liquidity of NeoGenomics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Neogenomics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 6.20 means the company has $6.20 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NeoGenomics Inc:

  • The MRQ is 6.197. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.358. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.197TTM6.358-0.161
TTM6.358YOY7.322-0.964
TTM6.3585Y6.454-0.096
5Y6.45410Y4.571+1.883
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1972.122+4.075
TTM6.3582.298+4.060
YOY7.3222.599+4.723
5Y6.4543.012+3.442
10Y4.5713.081+1.490
1.3.2. Quick Ratio

Measures if Neogenomics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • A Quick Ratio of 6.43 means the company can pay off $6.43 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NeoGenomics Inc:

  • The MRQ is 6.429. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.991. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.429TTM6.991-0.562
TTM6.991YOY8.828-1.836
TTM6.9915Y7.146-0.154
5Y7.14610Y4.755+2.391
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4291.215+5.214
TTM6.9911.319+5.672
YOY8.8281.661+7.167
5Y7.1461.957+5.189
10Y4.7552.295+2.460

1.4. Solvency of NeoGenomics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Neogenomics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Neogenomics to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.44 means that Neogenomics assets are financed with 44.0% credit (debt) and the remaining percentage (100% - 44.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NeoGenomics Inc:

  • The MRQ is 0.440. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.435. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.440TTM0.435+0.005
TTM0.435YOY0.420+0.015
TTM0.4355Y0.378+0.057
5Y0.37810Y0.371+0.007
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4400.429+0.011
TTM0.4350.407+0.028
YOY0.4200.394+0.026
5Y0.3780.450-0.072
10Y0.3710.450-0.079
1.4.2. Debt to Equity Ratio

Measures if Neogenomics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 78.6% means that company has $0.79 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NeoGenomics Inc:

  • The MRQ is 0.786. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.771. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.786TTM0.771+0.015
TTM0.771YOY0.724+0.047
TTM0.7715Y0.621+0.150
5Y0.62110Y0.611+0.010
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7860.606+0.180
TTM0.7710.571+0.200
YOY0.7240.631+0.093
5Y0.6210.658-0.037
10Y0.6110.734-0.123

2. Market Valuation of NeoGenomics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Neogenomics generates.

  • Above 15 is considered overpriced but always compare Neogenomics to the Diagnostics & Research industry mean.
  • A PE ratio of -36.03 means the investor is paying $-36.03 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NeoGenomics Inc:

  • The EOD is -33.893. Based on the earnings, the company is expensive. -2
  • The MRQ is -36.031. Based on the earnings, the company is expensive. -2
  • The TTM is -24.083. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-33.893MRQ-36.031+2.138
MRQ-36.031TTM-24.083-11.949
TTM-24.083YOY-8.914-15.168
TTM-24.0835Y26.600-50.683
5Y26.60010Y-4.067+30.667
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-33.893-0.239-33.654
MRQ-36.031-0.395-35.636
TTM-24.083-0.199-23.884
YOY-8.914-0.008-8.906
5Y26.6003.483+23.117
10Y-4.0674.432-8.499
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NeoGenomics Inc:

  • The EOD is 45.265. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 48.120. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is -18.324. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD45.265MRQ48.120-2.855
MRQ48.120TTM-18.324+66.444
TTM-18.324YOY-16.797-1.527
TTM-18.3245Y-71.630+53.306
5Y-71.63010Y-40.527-31.103
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD45.265-0.296+45.561
MRQ48.120-0.441+48.561
TTM-18.324-1.480-16.844
YOY-16.797-2.079-14.718
5Y-71.630-1.665-69.965
10Y-40.527-1.971-38.556
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Neogenomics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 2.19 means the investor is paying $2.19 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NeoGenomics Inc:

  • The EOD is 2.063. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.193. Based on the equity, the company is underpriced. +1
  • The TTM is 2.069. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.063MRQ2.193-0.130
MRQ2.193TTM2.069+0.124
TTM2.069YOY1.176+0.892
TTM2.0695Y4.540-2.472
5Y4.54010Y6.364-1.824
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD2.0631.962+0.101
MRQ2.1932.222-0.029
TTM2.0692.168-0.099
YOY1.1763.041-1.865
5Y4.5403.534+1.006
10Y6.3644.125+2.239
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of NeoGenomics Inc.

3.1. Institutions holding NeoGenomics Inc

Institutions are holding 100.865% of the shares of NeoGenomics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc15.65790.008219980993-121915-0.6065
2023-12-31Vanguard Group Inc11.10390.00514169665-146536-1.0236
2023-12-31Brown Advisory Holdings Inc7.55710.21939643599139739716.9459
2023-12-31T. Rowe Price Investment Management,Inc.5.00160.0672638251585629615.4952
2023-12-31HHG PLC4.9750.06136348613-825814-11.5105
2023-12-31State Street Corporation3.79670.00384844945-79544-1.6153
2023-12-31Goldman Sachs Group Inc3.58460.00664574290210715485.4089
2023-12-31Macquarie Group Ltd3.19820.07634081179106222635.1852
2023-09-30Greenhouse Funds LLLP3.11973.6199398100368618620.8262
2023-12-31First Light Asset Management, LLC3.07725.1116392675689784329.6424
2023-12-31Dimensional Fund Advisors, Inc.2.3560.01423006523186030.6226
2023-12-31Geode Capital Management, LLC2.21810.004828305351243214.5939
2023-12-31Schroder Investment Management Group1.94380.0522480424-32883-1.3084
2023-12-31American Century Companies Inc1.560.0221199069219638107305.2972
2023-12-31Morgan Stanley - Brokerage Accounts1.53950.00281964566-30882-1.5476
2023-12-31Emerald Advisers, LLC1.48721.31421897814-29260-1.5184
2023-12-31Fred Alger Management, LLC1.470.1638187583054413040.8598
2023-12-31Amvescap Plc.1.32780.00651694459-64676-3.6766
2023-12-31Northern Trust Corp1.25280.00471598640224981.4274
2023-12-31Emerald Mutual Fund Advisers Trust1.22081.3347155789500
Total 77.447912.09998830936+8348954+8.4%

3.2. Funds holding NeoGenomics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Core S&P Small-Cap ETF6.80380.17488682389129960.1499
2024-02-29Vanguard Total Stock Mkt Idx Inv3.13190.0043996590-96167-2.3497
2024-02-29Vanguard Small Cap Index2.57470.03653285586304700.9361
2024-02-29iShares Russell 2000 ETF2.41350.07713079880-503-0.0163
2024-02-29Brown Advisory Small-Cap Growth Inv2.38862.1219304808700
2023-12-31T. Rowe Price Small-Cap Stock2.29670.5011293080035980013.9946
2023-12-31T. Rowe Price US Small-Cap Core Equity2.29670.4999293080035980013.9946
2023-12-31Macquarie US Small Cap Core Equity1.93430.5343246839200
2024-01-31Delaware Small Cap Core I1.91140.51192439153-29239-1.1845
2023-12-31Janus Henderson US SMID Cap Growth1.8770.5707239522300
2023-12-31Janus Henderson Triton D1.8770.5683239522300
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.47670.0288188440214020.0745
2024-02-29Vanguard Small Cap Growth Index Inv1.44510.08241844080306561.6905
2023-12-31American Century Small Cap Growth Inv1.42610.9187181979318197930
2023-12-31American Century U.S. Small Cap Growth1.42610.9189181979318197930
2024-02-29Principal SmallCap Growth I Instl1.22380.971561720-106-0.0068
2023-12-31T. Rowe Price U.S. SC Core Eq Tr-Z1.12110.4961143061321270017.4643
2023-12-31T. Rowe Price Instl Small-Cap Stock1.06630.5003136068019800017.0296
2023-12-31Janus Henderson Venture D1.04040.7132770500
2023-12-31Janus Henderson US Small Cap Growth1.04040.7048132770500
Total 40.771610.920552028614+4719395+9.1%

3.3. Insider Transactions

Insiders are holding 1.215% of the shares of NeoGenomics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-15Alicia C OlivoSELL258714.96
2023-11-17Alicia C OlivoSELL266918.39

4. Summary

4.1. Key Performance Indicators

The key performance indicators of NeoGenomics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.046-0.111+140%-0.216+368%0.243-119%0.180-126%
Book Value Per Share--7.3787.483-1%8.090-9%6.462+14%3.875+90%
Current Ratio--6.1976.358-3%7.322-15%6.454-4%4.571+36%
Debt To Asset Ratio--0.4400.435+1%0.420+5%0.378+16%0.371+19%
Debt To Equity Ratio--0.7860.771+2%0.724+9%0.621+26%0.611+29%
Dividend Per Share----0%-0%-0%0.000-100%
Eps---0.112-0.172+54%-0.283+152%-0.090-20%-0.052-53%
Free Cash Flow Per Share--0.084-0.060+172%-0.190+326%-0.095+213%-0.036+143%
Free Cash Flow To Equity Per Share--0.094-0.051+154%-0.167+277%0.348-73%0.215-56%
Gross Profit Margin--2.2611.879+20%1.506+50%0.816+177%5.625-60%
Intrinsic Value_10Y_max--5.904--------
Intrinsic Value_10Y_min---2.994--------
Intrinsic Value_1Y_max---0.037--------
Intrinsic Value_1Y_min---0.527--------
Intrinsic Value_3Y_max--0.367--------
Intrinsic Value_3Y_min---1.395--------
Intrinsic Value_5Y_max--1.349--------
Intrinsic Value_5Y_min---2.053--------
Market Cap1942224200.000-6%2064729800.0001976678900.000+4%1217080375.000+70%3300274359.500-37%2152569652.250-4%
Net Profit Margin---0.092-0.151+64%-0.288+213%-0.088-5%-0.047-49%
Operating Margin---0.062-0.144+131%-0.312+400%-0.101+62%-0.058-6%
Operating Ratio--1.1121.165-5%1.312-15%1.147-3%1.069+4%
Pb Ratio2.063-6%2.1932.069+6%1.176+86%4.540-52%6.364-66%
Pe Ratio-33.893+6%-36.031-24.083-33%-8.914-75%26.600-235%-4.067-89%
Price Per Share15.220-6%16.18015.490+4%9.538+70%25.798-37%16.836-4%
Price To Free Cash Flow Ratio45.265-6%48.120-18.324+138%-16.797+135%-71.630+249%-40.527+184%
Price To Total Gains Ratio-329.693+6%-350.489-184.031-47%-48.602-86%-3.569-99%96.374-464%
Quick Ratio--6.4296.991-8%8.828-27%7.146-10%4.755+35%
Return On Assets---0.009-0.013+52%-0.020+137%-0.006-24%-0.004-59%
Return On Equity---0.015-0.023+51%-0.035+128%-0.012-24%-0.006-58%
Total Gains Per Share---0.046-0.111+140%-0.216+368%0.243-119%0.180-126%
Usd Book Value--941537000.000954904750.000-1%1032383500.000-9%826233650.000+14%495310950.000+90%
Usd Book Value Change Per Share---0.046-0.111+140%-0.216+368%0.243-119%0.180-126%
Usd Book Value Per Share--7.3787.483-1%8.090-9%6.462+14%3.875+90%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---0.112-0.172+54%-0.283+152%-0.090-20%-0.052-53%
Usd Free Cash Flow--10727000.000-7676250.000+172%-24221000.000+326%-12137500.000+213%-4603250.000+143%
Usd Free Cash Flow Per Share--0.084-0.060+172%-0.190+326%-0.095+213%-0.036+143%
Usd Free Cash Flow To Equity Per Share--0.094-0.051+154%-0.167+277%0.348-73%0.215-56%
Usd Market Cap1942224200.000-6%2064729800.0001976678900.000+4%1217080375.000+70%3300274359.500-37%2152569652.250-4%
Usd Price Per Share15.220-6%16.18015.490+4%9.538+70%25.798-37%16.836-4%
Usd Profit---14326000.000-21992000.000+54%-36062500.000+152%-11419400.000-20%-5842975.000-59%
Usd Revenue--155552000.000147910750.000+5%127432000.000+22%121948900.000+28%85132050.000+83%
Usd Total Gains Per Share---0.046-0.111+140%-0.216+368%0.243-119%0.180-126%
 EOD+4 -4MRQTTM+23 -11YOY+23 -115Y+13 -2110Y+12 -24

4.2. Fundamental Score

Let's check the fundamental score of NeoGenomics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-33.893
Price to Book Ratio (EOD)Between0-12.063
Net Profit Margin (MRQ)Greater than0-0.092
Operating Margin (MRQ)Greater than0-0.062
Quick Ratio (MRQ)Greater than16.429
Current Ratio (MRQ)Greater than16.197
Debt to Asset Ratio (MRQ)Less than10.440
Debt to Equity Ratio (MRQ)Less than10.786
Return on Equity (MRQ)Greater than0.15-0.015
Return on Assets (MRQ)Greater than0.05-0.009
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of NeoGenomics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.614
Ma 20Greater thanMa 5014.297
Ma 50Greater thanMa 10015.027
Ma 100Greater thanMa 20015.852
OpenGreater thanClose14.340
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
EBITDA  -23,31115,437-7,8742,386-5,4883,676-1,81210,4678,655



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,681,229
Total Liabilities739,692
Total Stockholder Equity941,537
 As reported
Total Liabilities 739,692
Total Stockholder Equity+ 941,537
Total Assets = 1,681,229

Assets

Total Assets1,681,229
Total Current Assets596,812
Long-term Assets1,084,417
Total Current Assets
Cash And Cash Equivalents 342,488
Short-term Investments 72,715
Net Receivables 131,227
Inventory 24,156
Other Current Assets 8,239
Total Current Assets  (as reported)596,812
Total Current Assets  (calculated)578,825
+/- 17,987
Long-term Assets
Property Plant Equipment 183,781
Goodwill 522,766
Intangible Assets 373,128
Long-term Assets Other 4,742
Long-term Assets  (as reported)1,084,417
Long-term Assets  (calculated)1,084,417
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities96,304
Long-term Liabilities643,388
Total Stockholder Equity941,537
Total Current Liabilities
Short-term Debt 5,610
Accounts payable 20,334
Other Current Liabilities 68,230
Total Current Liabilities  (as reported)96,304
Total Current Liabilities  (calculated)94,174
+/- 2,130
Long-term Liabilities
Long term Debt 538,198
Capital Lease Obligations 73,481
Long-term Liabilities Other 13,034
Long-term Liabilities  (as reported)643,388
Long-term Liabilities  (calculated)624,713
+/- 18,675
Total Stockholder Equity
Common Stock127
Accumulated Other Comprehensive Income -1,674
Other Stockholders Equity 941,537
Total Stockholder Equity (as reported)941,537
Total Stockholder Equity (calculated)939,990
+/- 1,547
Other
Capital Stock127
Cash and Short Term Investments 415,203
Common Stock Shares Outstanding 125,929
Current Deferred Revenue2,130
Liabilities and Stockholders Equity 1,681,229
Net Debt 269,191
Net Invested Capital 1,479,735
Net Working Capital 500,508
Property Plant and Equipment Gross 341,992
Short Long Term Debt Total 611,679



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-06-301999-03-31
> Total Assets 
0
0
267
214
4
0
0
0
0
81
81
316
468
448
448
489
484
507
531
627
757
592
592
793
999
1,080
1,080
2,323
2,971
3,132
3,132
6,323
6,521
6,521
6,513
7,666
8,027
7,295
7,295
9,382
12,917
12,945
14,218
14,651
14,281
13,651
15,400
16,658
17,485
19,949
26,440
28,001
29,302
30,071
33,616
34,459
35,230
39,916
42,319
43,638
78,820
81,106
81,158
82,966
83,741
367,955
346,844
351,556
355,427
337,118
343,637
339,880
343,895
343,340
349,272
345,783
455,139
505,015
533,343
696,667
711,155
709,506
732,247
945,485
959,428
988,331
1,494,413
1,896,311
1,906,387
1,869,778
1,829,547
1,792,113
1,755,582
1,740,034
1,709,174
1,695,108
1,678,241
1,681,229
1,681,2291,678,2411,695,1081,709,1741,740,0341,755,5821,792,1131,829,5471,869,7781,906,3871,896,3111,494,413988,331959,428945,485732,247709,506711,155696,667533,343505,015455,139345,783349,272343,340343,895339,880343,637337,118355,427351,556346,844367,95583,74182,96681,15881,10678,82043,63842,31939,91635,23034,45933,61630,07129,30228,00126,44019,94917,48516,65815,40013,65114,28114,65114,21812,94512,9179,3827,2957,2958,0277,6666,5136,5216,5216,3233,1323,1322,9712,3231,0801,08099979359259275762753150748448944844846831681810000421426700
   > Total Current Assets 
0
0
46
5
4
0
0
0
0
79
79
114
78
61
61
115
109
102
133
254
407
196
196
360
542
681
681
1,465
1,767
1,896
1,896
4,296
4,152
4,152
4,488
5,194
5,257
4,356
4,356
6,103
8,631
8,520
9,250
9,522
9,185
8,738
10,754
12,023
12,313
13,178
15,988
16,556
17,121
18,581
22,743
23,163
23,827
27,491
28,147
28,082
57,243
58,742
57,331
59,601
60,857
99,028
81,203
87,509
92,559
78,825
84,581
83,357
85,747
84,963
87,771
83,259
194,270
103,668
115,945
276,345
292,001
290,738
215,442
419,000
422,375
448,730
942,732
721,795
709,930
681,508
651,100
622,260
603,360
605,291
584,996
584,720
586,950
596,812
596,812586,950584,720584,996605,291603,360622,260651,100681,508709,930721,795942,732448,730422,375419,000215,442290,738292,001276,345115,945103,668194,27083,25987,77184,96385,74783,35784,58178,82592,55987,50981,20399,02860,85759,60157,33158,74257,24328,08228,14727,49123,82723,16322,74318,58117,12116,55615,98813,17812,31312,02310,7548,7389,1859,5229,2508,5208,6316,1034,3564,3565,2575,1944,4884,1524,1524,2961,8961,8961,7671,46568168154236019619640725413310210911561617811479790000454600
       Cash And Cash Equivalents 
0
0
5
2
4
0
0
0
0
77
77
35
24
0
2
14
40
25
55
191
324
113
113
21
77
11
11
274
412
126
126
810
211
211
1,622
442
631
468
468
698
3,128
1,631
1,661
2,177
1,555
1,097
2,533
2,632
2,649
2,628
2,756
2,566
2,038
1,868
4,628
4,636
4,929
4,834
5,385
5,023
34,366
33,689
31,248
32,952
33,966
23,420
19,256
21,786
28,935
12,525
11,036
10,932
12,211
12,821
15,173
9,435
118,440
9,811
13,195
167,436
178,891
173,016
86,254
295,281
233,233
228,713
611,970
368,796
340,565
316,827
305,896
283,637
266,126
263,180
275,609
289,074
306,239
342,488
342,488306,239289,074275,609263,180266,126283,637305,896316,827340,565368,796611,970228,713233,233295,28186,254173,016178,891167,43613,1959,811118,4409,43515,17312,82112,21110,93211,03612,52528,93521,78619,25623,42033,96632,95231,24833,68934,3665,0235,3854,8344,9294,6364,6281,8682,0382,5662,7562,6282,6492,6322,5331,0971,5552,1771,6611,6313,1286984684686314421,62221121181012612641227411117721113113324191552540142024357777000042500
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,000
500
500
500
500
500
500
500
300
300
300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,375
67,546
190,710
202,950
202,144
198,563
175,534
182,316
177,414
174,809
142,306
120,272
96,025
72,715
72,71596,025120,272142,306174,809177,414182,316175,534198,563202,144202,950190,71067,54650,37500000000000000000000000000000003003003005005005005005005005001,0001,00000000000000000000000000000000000000000000
       Net Receivables 
0
0
41
3
0
0
0
0
0
0
0
8
31
40
40
69
49
64
68
50
66
56
56
278
374
551
551
1,033
1,136
1,550
1,550
2,809
3,237
3,237
2,272
3,642
3,381
2,914
2,914
4,171
4,175
4,632
5,492
5,385
5,630
5,236
6,191
7,155
7,366
7,894
10,683
11,327
12,013
14,034
15,628
16,005
15,727
18,653
19,262
18,800
18,297
20,475
21,484
21,130
21,556
48,943
50,088
53,513
50,184
55,512
61,718
61,750
62,723
60,427
58,129
60,765
62,694
76,919
82,585
89,991
91,133
94,242
99,972
87,766
103,697
106,843
102,922
106,284
104,964
112,130
110,796
111,276
111,994
119,711
118,842
125,425
132,640
131,227
131,227132,640125,425118,842119,711111,994111,276110,796112,130104,964106,284102,922106,843103,69787,76699,97294,24291,13389,99182,58576,91962,69460,76558,12960,42762,72361,75061,71855,51250,18453,51350,08848,94321,55621,13021,48420,47518,29718,80019,26218,65315,72716,00515,62814,03412,01311,32710,6837,8947,3667,1556,1915,2365,6305,3855,4924,6324,1754,1712,9142,9143,3813,6422,2723,2373,2372,8091,5501,5501,1361,03355155137427856566650686449694040318000000034100
       Other Current Assets 
0
0
0
0
0
0
0
0
0
1
1
51
8
2
2
8
7
3
0
3
11
12
12
30
47
59
59
82
160
102
102
260
400
400
232
746
900
482
482
635
714
655
1,097
653
732
1,018
619
657
702
954
937
837
864
820
2,487
2,522
3,171
4,004
3,500
4,259
4,580
4,578
4,599
5,519
5,335
4,889
6,525
6,665
7,488
4,535
5,857
5,218
4,725
4,241
6,954
6,161
6,307
8,288
10,495
10,185
9,345
9,075
8,930
14,326
14,427
4,555
4,675
8,422
15,755
8,189
20,693
6,506
7,516
8,077
7,622
8,433
9,317
8,239
8,2399,3178,4337,6228,0777,5166,50620,6938,18915,7558,4224,6754,55514,42714,3268,9309,0759,34510,18510,4958,2886,3076,1616,9544,2414,7255,2185,8574,5357,4886,6656,5254,8895,3355,5194,5994,5784,5804,2593,5004,0043,1712,5222,4878208648379379547026576191,0187326531,0976557146354824829007462324004002601021021608259594730121211303782285111000000000
   > Long-term Assets 
0
0
221
209
-5
0
0
0
0
3
3
203
390
386
386
374
375
405
398
373
350
396
396
434
457
400
400
858
1,204
0
1,236
2,027
2,369
2,369
2,025
2,471
2,770
2,940
2,940
3,279
4,287
4,425
4,968
5,129
5,096
4,913
4,646
4,635
5,172
6,771
10,452
11,445
12,181
11,490
10,873
11,296
11,403
12,425
14,172
15,556
21,577
22,364
23,827
23,365
22,884
268,927
265,641
264,047
262,868
258,293
259,056
256,523
258,148
258,377
261,501
262,524
260,869
401,347
417,398
420,322
419,154
418,768
516,805
526,485
537,053
539,601
551,681
1,174,516
1,196,457
1,188,270
1,178,447
1,169,853
1,152,222
1,134,743
1,124,178
1,110,388
1,091,291
1,084,417
1,084,4171,091,2911,110,3881,124,1781,134,7431,152,2221,169,8531,178,4471,188,2701,196,4571,174,516551,681539,601537,053526,485516,805418,768419,154420,322417,398401,347260,869262,524261,501258,377258,148256,523259,056258,293262,868264,047265,641268,92722,88423,36523,82722,36421,57715,55614,17212,42511,40311,29610,87311,49012,18111,44510,4526,7715,1724,6354,6464,9135,0965,1294,9684,4254,2873,2792,9402,9402,7702,4712,0252,3692,3692,0271,23601,204858400400457434396396350373398405375374386386390203330000-520922100
       Property Plant Equipment 
0
0
35
33
-5
0
0
0
0
3
3
203
390
383
383
373
375
398
396
371
347
393
393
413
443
382
382
839
1,171
1,202
1,202
1,777
2,108
2,108
1,774
2,216
2,495
2,875
2,875
3,191
4,180
4,340
4,882
5,042
5,010
4,839
4,553
4,559
5,062
6,642
7,355
8,410
9,234
8,607
8,045
8,437
8,592
9,694
11,472
12,974
14,637
15,082
16,640
16,286
15,898
34,577
33,559
33,575
34,169
34,036
36,531
35,588
34,549
36,504
40,411
42,873
41,004
60,888
80,430
85,391
88,285
90,680
135,792
137,607
141,447
151,888
166,271
191,724
209,482
211,662
210,897
211,022
205,763
198,608
196,629
191,522
181,648
183,781
183,781181,648191,522196,629198,608205,763211,022210,897211,662209,482191,724166,271151,888141,447137,607135,79290,68088,28585,39180,43060,88841,00442,87340,41136,50434,54935,58836,53134,03634,16933,57533,55934,57715,89816,28616,64015,08214,63712,97411,4729,6948,5928,4378,0458,6079,2348,4107,3556,6425,0624,5594,5534,8395,0105,0424,8824,3404,1803,1912,8752,8752,4952,2161,7742,1082,1081,7771,2021,2021,171839382382443413393393347371396398375373383383390203330000-5333500
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,968
2,912
2,856
2,800
2,744
2,689
2,633
2,577
2,521
2,466
2,561
2,929
2,929
2,929
2,929
146,421
146,179
146,179
146,179
147,019
147,019
147,019
147,019
147,019
147,019
147,019
147,019
197,892
196,298
196,298
198,571
198,601
210,833
210,833
210,833
211,083
211,083
499,977
525,802
527,115
527,115
527,115
522,766
522,766
522,766
522,766
522,766
522,766
522,766522,766522,766522,766522,766522,766527,115527,115527,115525,802499,977211,083211,083210,833210,833210,833198,601198,571196,298196,298197,892147,019147,019147,019147,019147,019147,019147,019147,019146,179146,179146,179146,4212,9292,9292,9292,9292,5612,4662,5212,5772,6332,6892,7442,8002,8562,9122,96800000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
400
600
400
600
500
300
100
40
0
0
13,137
25,600
29,555
10,185
0
0
0
0
0
0
0
0
0
0
0
0000000000010,18529,55525,60013,13700401003005006004006004000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
186
176
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,968
2,912
2,856
2,800
2,744
2,689
2,633
2,577
2,521
2,466
4,236
4,212
4,119
4,022
3,928
87,800
85,774
84,164
82,346
77,064
75,339
73,614
76,330
74,165
72,751
71,330
69,909
140,029
137,844
135,301
129,084
126,640
128,289
125,821
123,353
120,653
118,195
471,038
450,802
442,325
433,835
425,338
416,848
408,260
399,477
390,693
381,910
373,128
373,128381,910390,693399,477408,260416,848425,338433,835442,325450,802471,038118,195120,653123,353125,821128,289126,640129,084135,301137,844140,02969,90971,33072,75174,16576,33073,61475,33977,06482,34684,16485,77487,8003,9284,0224,1194,2124,2362,4662,5212,5772,6332,6892,7442,8002,8562,9122,968000000000000000000000000000000000000000000000017618600
       Other Assets 
0
0
187
176
5
0
0
0
0
0
0
0
0
4
1
1
0
7
2
2
3
3
34
20
14
17
13
19
33
34
40
251
251
261
248
256
275
65
73
88
107
85
86
87
86
74
93
76
110
129
3,097
3,035
2,947
0
2,828
2,859
2,811
2,731
2,700
2,582
6,940
7,282
7,187
7,079
6,986
234,350
232,082
230,472
228,699
224,257
222,525
220,935
223,599
221,873
720
902
2,337
2,038
2,826
3,332
3,174
2,847
45,207
45,171
67,043
54,446
47,629
36,735
10,371
7,168
6,600
6,378
6,845
5,109
5,306
5,407
0
0
005,4075,3065,1096,8456,3786,6007,16810,37136,73547,62954,44667,04345,17145,2072,8473,1743,3322,8262,0382,337902720221,873223,599220,935222,525224,257228,699230,472232,082234,3506,9867,0797,1877,2826,9402,5822,7002,7312,8112,8592,82802,9473,0353,0971291107693748687868510788736527525624826125125140343319131714203433227011400000000517618700
> Total Liabilities 
0
0
337
422
552
125
125
323
227
186
186
459
374
424
424
584
708
875
1,021
989
894
1,019
1,019
1,283
1,702
2,075
2,075
2,428
2,744
3,077
3,077
2,461
4,199
4,199
2,163
5,335
5,540
5,794
5,794
7,034
5,870
7,302
9,115
10,268
10,906
10,516
10,014
11,369
12,125
14,052
17,770
18,282
20,080
20,855
14,786
15,019
14,903
18,205
19,824
20,505
19,755
20,701
21,003
22,099
21,892
129,843
106,672
108,188
109,335
150,522
156,173
143,306
144,237
137,807
141,256
181,574
151,580
184,572
209,495
206,933
214,148
202,098
227,204
291,256
293,065
294,037
650,699
747,953
769,142
761,501
754,543
748,594
742,594
742,011
734,712
738,916
730,813
739,692
739,692730,813738,916734,712742,011742,594748,594754,543761,501769,142747,953650,699294,037293,065291,256227,204202,098214,148206,933209,495184,572151,580181,574141,256137,807144,237143,306156,173150,522109,335108,188106,672129,84321,89222,09921,00320,70119,75520,50519,82418,20514,90315,01914,78620,85520,08018,28217,77014,05212,12511,36910,01410,51610,90610,2689,1157,3025,8707,0345,7945,7945,5405,3352,1634,1994,1992,4613,0773,0772,7442,4282,0752,0751,7021,2831,0191,0198949891,02187570858442442437445918618622732312512555242233700
   > Total Current Liabilities 
0
0
317
405
535
125
125
323
227
186
186
459
374
424
424
210
214
285
306
989
894
1,019
1,019
266
438
666
666
788
801
2,628
2,628
1,748
3,362
3,362
1,564
4,480
4,486
4,391
4,391
5,503
4,304
5,776
7,484
8,832
9,517
9,168
8,799
10,112
10,539
11,444
14,749
15,096
16,670
17,758
11,949
12,056
12,246
14,323
15,227
15,226
13,954
14,623
13,855
15,125
15,328
40,058
34,316
34,953
35,392
59,912
39,876
35,204
40,114
35,065
43,303
47,974
47,055
60,925
72,703
59,162
68,907
63,904
67,649
61,700
64,612
73,183
67,750
99,131
92,737
87,232
82,070
82,670
85,003
89,932
86,606
94,848
92,926
96,304
96,30492,92694,84886,60689,93285,00382,67082,07087,23292,73799,13167,75073,18364,61261,70067,64963,90468,90759,16272,70360,92547,05547,97443,30335,06540,11435,20439,87659,91235,39234,95334,31640,05815,32815,12513,85514,62313,95415,22615,22714,32312,24612,05611,94917,75816,67015,09614,74911,44410,53910,1128,7999,1689,5178,8327,4845,7764,3045,5034,3914,3914,4864,4801,5643,3623,3621,7482,6282,6288017886666664382661,0191,01989498930628521421042442437445918618622732312512553540531700
       Short-term Debt 
0
0
11
11
11
0
0
0
0
0
0
0
0
0
14
0
0
46
60
54
729
0
72
0
0
0
23
84
72
94
94
185
243
243
153
1,374
1,626
1,784
1,784
2,728
996
2,034
4,276
5,000
5,943
5,437
5,744
5,675
6,338
6,005
8,998
8,957
10,548
10,670
6,473
5,747
5,336
7,068
7,855
5,083
3,157
3,224
3,759
3,895
4,203
14,003
4,863
5,337
5,646
30,532
8,834
8,642
8,486
8,989
10,207
12,409
13,892
14,172
17,994
14,253
15,527
13,813
14,446
8,954
8,401
7,808
7,200
7,555
8,552
8,019
6,579
6,118
6,497
6,654
6,972
7,365
6,217
5,610
5,6106,2177,3656,9726,6546,4976,1186,5798,0198,5527,5557,2007,8088,4018,95414,44613,81315,52714,25317,99414,17213,89212,40910,2078,9898,4868,6428,83430,5325,6465,3374,86314,0034,2033,8953,7593,2243,1575,0837,8557,0685,3365,7476,47310,67010,5488,9578,9986,0056,3385,6755,7445,4375,9435,0004,2762,0349962,7281,7841,7841,6261,3741532432431859494728423000720729546046001400000000011111100
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66
0
0
0
600
4,863
5,337
5,646
3,842
8,834
109,309
3,799
3,799
4,219
6,562
7,217
7,873
7,873
5,000
6,250
5,000
5,000
0
0
0
0
1,913
0
0
621
0
0
0
0
0
0
0
0000000621001,91300005,0005,0006,2505,0007,8737,8737,2176,5624,2193,7993,799109,3098,8343,8425,6465,3374,863600000660000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
23
54
72
10
10
174
10
19
19
115
210
120
120
54
56
70
77
27
11
96
96
136
275
464
464
433
402
698
698
989
1,799
1,799
949
1,903
1,905
1,512
1,512
1,554
2,107
1,969
1,762
2,049
1,869
1,933
1,722
2,463
2,285
2,529
3,316
3,134
3,238
3,611
2,925
3,387
3,780
4,177
4,701
6,081
6,287
6,294
5,465
6,059
5,026
26,055
29,453
29,616
29,746
29,380
31,042
26,562
31,628
26,076
33,096
35,565
33,163
46,753
54,709
44,909
53,380
50,091
53,203
52,746
56,211
65,375
18,919
23,056
28,536
17,921
20,481
16,849
13,708
83,278
79,634
87,483
16,819
20,334
20,33416,81987,48379,63483,27813,70816,84920,48117,92128,53623,05618,91965,37556,21152,74653,20350,09153,38044,90954,70946,75333,16335,56533,09626,07631,62826,56231,04229,38029,74629,61629,45326,0555,0266,0595,4656,2946,2876,0814,7014,1773,7803,3872,9253,6113,2383,1343,3162,5292,2852,4631,7221,9331,8692,0491,7621,9692,1071,5541,5121,5121,9051,9039491,7991,7999896986984024334644642751369696112777705654120120210115191910174101072542300
       Other Current Liabilities 
0
0
283
339
452
115
115
150
217
167
167
344
164
205
191
56
58
59
59
798
44
812
740
19
54
102
102
181
236
1,836
1,636
573
375
1,320
461
1,203
955
1,095
1,095
1,221
1,201
1,773
1,446
1,783
1,705
1,798
1,333
1,974
1,916
2,910
2,435
3,005
2,884
3,477
2,551
2,922
3,130
3,078
2,671
4,062
4,510
5,105
4,631
5,171
6,099
-16,668
14,165
16,181
15,762
-14,973
10,463
10,968
16,805
-6,307
20,048
-2,155
-1,259
-927
-1,017
-1,069
-1,187
-1,610
-2,974
-3,570
-3,716
-4,029
37,639
64,023
50,371
56,100
48,891
53,355
58,412
-7,557
-6,067
-5,712
66,273
68,230
68,23066,273-5,712-6,067-7,55758,41253,35548,89156,10050,37164,02337,639-4,029-3,716-3,570-2,974-1,610-1,187-1,069-1,017-927-1,259-2,15520,048-6,30716,80510,96810,463-14,97315,76216,18114,165-16,6686,0995,1714,6315,1054,5104,0622,6713,0783,1302,9222,5513,4772,8843,0052,4352,9101,9161,9741,3331,7981,7051,7831,4461,7731,2011,2211,0951,0959551,2034611,3203755731,6361,8362361811021025419740812447985959585619120516434416716721715011511545233928300
   > Long-term Liabilities 
0
0
20
17
17
0
10
174
10
0
19
115
210
0
233
374
494
590
715
137
850
0
206
1,017
1,263
1,409
1,409
1,640
1,944
0
449
713
837
837
599
854
1,054
1,403
1,403
1,531
1,566
1,526
1,631
1,436
1,389
1,348
1,215
1,257
1,586
2,608
3,021
3,186
3,410
3,097
2,837
2,963
2,657
3,882
4,597
5,279
5,801
6,078
7,148
6,974
6,564
89,785
72,356
73,235
73,943
90,610
116,297
108,102
104,123
102,742
97,953
133,600
104,525
123,647
136,792
147,771
145,241
138,194
159,555
229,556
228,453
220,854
582,949
648,822
676,405
674,269
672,473
665,924
657,591
652,079
648,106
644,068
637,887
643,388
643,388637,887644,068648,106652,079657,591665,924672,473674,269676,405648,822582,949220,854228,453229,556159,555138,194145,241147,771136,792123,647104,525133,60097,953102,742104,123108,102116,29790,61073,94373,23572,35689,7856,5646,9747,1486,0785,8015,2794,5973,8822,6572,9632,8373,0973,4103,1863,0212,6081,5861,2571,2151,3481,3891,4361,6311,5261,5661,5311,4031,4031,05485459983783771344901,9441,6401,4091,4091,2631,017206085013771559049437423302101151901017410017172000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,257
1,586
2,608
3,021
3,186
3,410
3,097
2,837
2,963
2,657
3,294
4,009
4,691
5,213
5,257
6,327
6,153
5,743
5,040
56,440
56,986
57,707
97,326
102,154
100,667
96,575
96,415
84,322
120,711
89,764
98,130
90,995
94,250
93,027
115,863
90,605
164,544
166,440
168,120
530,378
531,077
531,779
532,483
533,189
533,898
534,609
535,322
536,037
536,755
0
0
00536,755536,037535,322534,609533,898533,189532,483531,779531,077530,378168,120166,440164,54490,605115,86393,02794,25090,99598,13089,764120,71184,32296,41596,575100,667102,15497,32657,70756,98656,4405,0405,7436,1536,3275,2575,2134,6914,0093,2942,6572,9632,8373,0973,4103,1863,0212,6081,5861,25700000000000000000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,602
34,169
39,735
45,302
22,873
25,439
27,676
30,125
32,615
35,471
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000035,47132,61530,12527,67625,43922,87345,30239,73534,16928,60200000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
59
374
494
0
0
0
0
0
766
1,016
1,264
1,409
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
821
0
0
0
15,741
0
0
0
14,973
7,583
7,435
7,548
6,971
7,116
7,475
8,098
25,517
22,596
22,460
22,062
17,132
17,312
18,577
17,491
10,438
6,134
68,121
72,138
69,497
65,850
60,144
52,511
47,805
44,750
41,845
0
0
0041,84544,75047,80552,51160,14465,85069,49772,13868,1216,13410,43817,49118,57717,31217,13222,06222,46022,59625,5178,0987,4757,1166,9717,5487,4357,58314,97300015,741000821000000000000000000000000000000000001,4091,2641,016766000004943745900000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
588
588
588
588
821
821
821
821
32,409
15,916
16,249
16,236
14,973
7,583
7,435
7,548
6,307
6,594
6,827
6,899
22,457
20,156
20,117
19,688
15,566
16,377
15,422
13,554
5,415
1,744
940
57,706
55,475
51,709
45,979
38,345
34,750
31,715
28,811
0
0
0028,81131,71534,75038,34545,97951,70955,47557,7069401,7445,41513,55415,42216,37715,56619,68820,11720,15622,4576,8996,8276,5946,3077,5487,4357,58314,97316,23616,24915,91632,409821821821821588588588588000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
-69
-208
-548
0
-125
-323
-227
0
-105
-142
94
23
23
-95
-224
-368
-490
-362
-137
-427
-427
-489
-703
-995
-995
-105
227
55
55
3,863
2,322
2,322
4,350
2,331
2,487
1,501
1,501
2,348
7,048
5,643
5,103
4,383
3,375
3,135
5,386
5,289
5,360
5,897
8,670
9,719
9,222
9,216
18,830
19,440
20,327
21,711
22,495
23,133
59,065
60,405
60,155
60,867
61,849
238,112
240,172
243,368
246,092
186,596
187,464
196,574
199,658
205,533
208,016
164,209
303,559
320,443
323,848
489,734
497,007
507,408
505,043
654,229
666,363
694,294
843,714
1,148,358
1,137,245
1,108,277
1,075,004
1,043,519
1,012,988
998,023
974,462
956,192
947,428
941,537
941,537947,428956,192974,462998,0231,012,9881,043,5191,075,0041,108,2771,137,2451,148,358843,714694,294666,363654,229505,043507,408497,007489,734323,848320,443303,559164,209208,016205,533199,658196,574187,464186,596246,092243,368240,172238,11261,84960,86760,15560,40559,06523,13322,49521,71120,32719,44018,8309,2169,2229,7198,6705,8975,3605,2895,3863,1353,3754,3835,1035,6437,0482,3481,5011,5012,4872,3314,3502,3222,3223,8635555227-105-995-995-703-489-427-427-137-362-490-368-224-95232394-142-1050-227-323-1250-548-208-6900
   Common Stock
0
0
573
651
662
1,322
1,322
1,683
2,068
405
405
414
441
4
4
18
18
18
19
20
22
22
22
22
23
23
23
26
27
27
27
31
31
31
31
31
32
32
32
33
37
37
37
37
37
37
43
43
43
43
45
45
45
45
49
49
49
49
50
50
60
60
60
61
61
76
77
78
78
79
79
79
80
80
81
81
93
94
95
104
104
105
105
110
111
112
117
123
123
124
125
126
127
127
127
127
127
127
12712712712712712712612512412312311711211111010510510410495949381818080797979787877766161606060505049494949454545454343434337373737373733323232313131313127272726232323222222222019181818444414144054052,0681,6831,3221,32266265157300
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-22,645
-22,788
-22,636
-22,034
-21,483
-22,458
-22,571
-22,568
-22,295
-21,395
-20,538
-20,435
-20,161
-20,452
-19,406
-20,167
-20,342
-20,468
-21,941
-27,475
-32,628
-38,263
-52,460
-49,120
-51,803
-59,553
-57,466
-60,074
-53,580
-51,557
-51,258
-53,682
-51,691
-17,653
-11,357
-18,335
-25,159
-22,602
-7,185
-28,603
47,270
26,922
-14,837
-64,245
-99,548
-136,400
-159,087
-189,882
-214,213
0
0
00-214,213-189,882-159,087-136,400-99,548-64,245-14,83726,92247,270-28,603-7,185-22,602-25,159-18,335-11,357-17,653-51,691-53,682-51,258-51,557-53,580-60,074-57,466-59,553-51,803-49,120-52,460-38,263-32,628-27,475-21,941-20,468-20,342-20,167-19,406-20,452-20,161-20,435-20,538-21,395-22,295-22,568-22,571-22,458-21,483-22,034-22,636-22,788-22,64500000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-3
-5
-5
0
0
0
0
0
-3,791
-9,399
-2,315
-38
-38
-62
-75
-536
-101
-126
-151
-137
-29
-193
-226
-261
-3
-79
-111
-495
-123
-222
-222
-862
-221
-1,186
-1,375
-1,603
-1,840
-2,106
-2,416
-2,787
-3,202
-3,624
-4,084
-4,568
-5,056
-5,530
-6,052
-6,652
-7,402
-8,258
-9,202
-10,289
-11,279
-12,341
-13,404
-14,478
-15,629
-16,877
-18,416
-19,822
-21,406
-23,069
-24,791
-26,534
-30,135
-33,858
-37,840
-27,102
-31,012
-34,604
-37,496
274
499
257
536
-579
-1,136
-2,163
-2,380
-1,618
-2,656
43
22
10
-150
-333
-390
-638
-3,009
-4,056
-5,104
-3,899
-2,834
-2,572
-1,846
-1,674
-1,674-1,846-2,572-2,834-3,899-5,104-4,056-3,009-638-390-333-150102243-2,656-1,618-2,380-2,163-1,136-579536257499274-37,496-34,604-31,012-27,102-37,840-33,858-30,135-26,534-24,791-23,069-21,406-19,822-18,416-16,877-15,629-14,478-13,404-12,341-11,279-10,289-9,202-8,258-7,402-6,652-6,052-5,530-5,056-4,568-4,084-3,624-3,202-2,787-2,416-2,106-1,840-1,603-1,375-1,186-221-862-222-222-123-495-111-79-3-261-226-193-29-137-151-126-101-536-75-62-38-38-2,315-9,399-3,79100000-5-5-300
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,891
28,105
28,490
30,659
31,157
31,635
31,742
41,349
41,686
41,673
42,200
42,880
43,244
79,457
79,751
80,262
81,148
82,256
231,375
233,401
236,183
238,975
216,104
217,626
220,622
229,006
230,030
232,039
217,451
354,487
372,186
378,571
543,484
516,936
520,278
525,929
679,235
688,832
701,357
872,350
1,101,298
1,110,590
1,123,628
1,142,133
1,146,997
1,154,365
1,160,882
1,167,051
1,172,850
0
0
001,172,8501,167,0511,160,8821,154,3651,146,9971,142,1331,123,6281,110,5901,101,298872,350701,357688,832679,235525,929520,278516,936543,484378,571372,186354,487217,451232,039230,030229,006220,622217,626216,104238,975236,183233,401231,37582,25681,14880,26279,75179,45743,24442,88042,20041,67341,68641,34931,74231,63531,15730,65928,49028,10527,89100000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
11,359
11,650
12,100
8,726
8,726
8,871
8,893
8,818
8,966
9,287
9,706
9,712
9,604
10,101
10,160
10,264
10,005
10,701
11,032
0
11,300
16,987
16,821
16,821
16,883
17,023
17,374
17,382
17,382
20,292
26,054
26,548
27,174
27,853
28,504
29,125
32,752
33,421
34,157
35,142
38,061
39,415
40,837
42,031
52,628
54,027
55,077
56,678
58,509
60,121
97,873
99,573
101,668
104,217
107,047
257,909
263,536
270,041
276,815
243,206
242,078
254,824
266,502
230,030
232,039
-128,332
-100,652
372,186
378,571
543,484
516,936
520,278
525,929
679,235
688,832
701,357
872,350
1,101,298
1,110,590
1,123,628
1,142,133
1,146,997
1,154,365
1,160,882
1,167,051
1,172,850
1,181,876
941,537
941,5371,181,8761,172,8501,167,0511,160,8821,154,3651,146,9971,142,1331,123,6281,110,5901,101,298872,350701,357688,832679,235525,929520,278516,936543,484378,571372,186-100,652-128,332232,039230,030266,502254,824242,078243,206276,815270,041263,536257,909107,047104,217101,66899,57397,87360,12158,50956,67855,07754,02752,62842,03140,83739,41538,06135,14234,15733,42132,75229,12528,50427,85327,17426,54826,05420,29217,38217,38217,37417,02316,88316,82116,82116,98711,300011,03210,70110,00510,26410,16010,1019,6049,7129,7069,2878,9668,8188,8938,8718,7268,72612,10011,65011,3590000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue591,643
Cost of Revenue-347,039
Gross Profit244,604244,604
 
Operating Income (+$)
Gross Profit244,604
Operating Expense-341,252
Operating Income-107,736-96,648
 
Operating Expense (+$)
Research Development27,309
Selling General Administrative243,101
Selling And Marketing Expenses70,842
Operating Expense341,252341,252
 
Net Interest Income (+$)
Interest Income16,902
Interest Expense-6,907
Other Finance Cost-0
Net Interest Income9,995
 
Pretax Income (+$)
Operating Income-107,736
Net Interest Income9,995
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-97,097-97,292
EBIT - interestExpense = -86,009
-97,097
-81,061
Interest Expense6,907
Earnings Before Interest and Taxes (EBIT)-79,102-90,190
Earnings Before Interest and Taxes (EBITDA)-6,519
 
After tax Income (+$)
Income Before Tax-97,097
Tax Provision--9,129
Net Income From Continuing Ops-87,968-87,968
Net Income-87,968
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses688,291
Total Other Income/Expenses Net-10,444-9,995
 

Technical Analysis of Neogenomics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neogenomics. The general trend of Neogenomics is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neogenomics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NeoGenomics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 15.46 < 15.57 < 15.86.

The bearish price targets are: 13.34 > 13.33 > 11.03.

Tweet this
NeoGenomics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NeoGenomics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NeoGenomics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NeoGenomics Inc. The current macd is -0.22431464.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neogenomics price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Neogenomics. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Neogenomics price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
NeoGenomics Inc Daily Moving Average Convergence/Divergence (MACD) ChartNeoGenomics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NeoGenomics Inc. The current adx is 13.30.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Neogenomics shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
NeoGenomics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NeoGenomics Inc. The current sar is 13.41.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
NeoGenomics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NeoGenomics Inc. The current rsi is 58.61. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
NeoGenomics Inc Daily Relative Strength Index (RSI) ChartNeoGenomics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NeoGenomics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neogenomics price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
NeoGenomics Inc Daily Stochastic Oscillator ChartNeoGenomics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NeoGenomics Inc. The current cci is 116.91.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
NeoGenomics Inc Daily Commodity Channel Index (CCI) ChartNeoGenomics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NeoGenomics Inc. The current cmo is 32.50.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
NeoGenomics Inc Daily Chande Momentum Oscillator (CMO) ChartNeoGenomics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NeoGenomics Inc. The current willr is -30.62730627.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Neogenomics is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
NeoGenomics Inc Daily Williams %R ChartNeoGenomics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NeoGenomics Inc.

NeoGenomics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NeoGenomics Inc. The current atr is 0.69683242.

NeoGenomics Inc Daily Average True Range (ATR) ChartNeoGenomics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NeoGenomics Inc. The current obv is 21,216,080.

NeoGenomics Inc Daily On-Balance Volume (OBV) ChartNeoGenomics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NeoGenomics Inc. The current mfi is 53.38.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
NeoGenomics Inc Daily Money Flow Index (MFI) ChartNeoGenomics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NeoGenomics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

NeoGenomics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NeoGenomics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.614
Ma 20Greater thanMa 5014.297
Ma 50Greater thanMa 10015.027
Ma 100Greater thanMa 20015.852
OpenGreater thanClose14.340
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Neogenomics with someone you think should read this too:
  • Are you bullish or bearish on Neogenomics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neogenomics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NeoGenomics Inc

I send you an email if I find something interesting about NeoGenomics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about NeoGenomics Inc.

Receive notifications about NeoGenomics Inc in your mailbox!